Mian Ling Chen1, Chi Hua Fang, Liu Sen Liang, Li Hua Dai, Xiao Kang Wang. 1. Department of General Surgery, First Municipal People's Hospital of Guang Zhou, Guang Zhou Medical College, No. 1, Pan Fu Road, Guang Zhou, Guang Dong 510180, PR China. chenmianling@sina.com
Abstract
BACKGROUND: We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer. METHODS: Two independent researchers identified and extracted all relevant literature using MEDLINE and the Cochrane Library Database. The regimens included arm A (FU/LV) and arm B (FU/LV/Oxaliplatin) with no other chemotherapy agent. RESULTS: Five randomized controlled trials (RCTs) fulfilled the requirements. All RCTs showed superiority of FU/LV/Oxaliplatin to FU/LV when measuring RR (response rate) and PFS (progression-free survival); no significant improvement in OS (overall survival) was observed. This meta-analysis shows a better RR for the FU/LV/Oxaliplatin group (OR 4.02, 95% CI 2.37-6.82, p<0.00001). The incidence of grade 3/4 toxicities, including neutropenia, thrombocytopenia, vomiting, neurological toxicity, toxicity-related dose modification and discontinuation was higher in the FU/LV/Oxaliplatin group, while the incidence of anemia, nausea and diarrhea was not different. CONCLUSION: FU/LV/Oxaliplatin offers better efficacy (RR and PFS) than FU/LV in the treatment of advanced colorectal cancer. The incidence of grade 3/4 toxicities, i.e. neutropenia, thrombocytopenia, vomiting, neurological toxicity, is significantly higher in the FU/LV/Oxaliplatin than in the FU/LV group but these are manageable or reversible. Copyright 2009 Elsevier Ltd. All rights reserved.
BACKGROUND: We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer. METHODS: Two independent researchers identified and extracted all relevant literature using MEDLINE and the Cochrane Library Database. The regimens included arm A (FU/LV) and arm B (FU/LV/Oxaliplatin) with no other chemotherapy agent. RESULTS: Five randomized controlled trials (RCTs) fulfilled the requirements. All RCTs showed superiority of FU/LV/Oxaliplatin to FU/LV when measuring RR (response rate) and PFS (progression-free survival); no significant improvement in OS (overall survival) was observed. This meta-analysis shows a better RR for the FU/LV/Oxaliplatin group (OR 4.02, 95% CI 2.37-6.82, p<0.00001). The incidence of grade 3/4 toxicities, including neutropenia, thrombocytopenia, vomiting, neurological toxicity, toxicity-related dose modification and discontinuation was higher in the FU/LV/Oxaliplatin group, while the incidence of anemia, nausea and diarrhea was not different. CONCLUSION: FU/LV/Oxaliplatin offers better efficacy (RR and PFS) than FU/LV in the treatment of advanced colorectal cancer. The incidence of grade 3/4 toxicities, i.e. neutropenia, thrombocytopenia, vomiting, neurological toxicity, is significantly higher in the FU/LV/Oxaliplatin than in the FU/LV group but these are manageable or reversible. Copyright 2009 Elsevier Ltd. All rights reserved.
Authors: Yang Zhang; Yi Zhang; Liying Geng; Haowei Yi; Wei Huo; Geoffrey Talmon; Yeong C Kim; San Ming Wang; Jing Wang Journal: J Biol Chem Date: 2016-06-21 Impact factor: 5.157
Authors: Satya Narayan; Aruna S Jaiswal; Ritika Sharma; Akbar Nawab; Lizette Vila Duckworth; Brian K Law; Maria Zajac-Kaye; Thomas J George; Jay Sharma; Arun K Sharma; Robert A Hromas Journal: Oncotarget Date: 2017-08-01
Authors: Annick De Weerdt; Amélie Dendooven; Annemie Snoeckx; Jan Pen; Martin Lammens; Philippe G Jorens Journal: BMC Cancer Date: 2017-08-29 Impact factor: 4.430